2010-024023-25: ENSAYO CLÍNICO, ABIERTO, DE GRUPOS PARALELOS, FASE III, PARA VALORAR EL EFECTO ANTIPROTEINÚRICO DE LOS DERIVADOS DE LA VITAMINA D EN PACIENTES CON ENFERMEDAD RENAL CRÓNICA E INSUFICIENCIA DE VITAMINA D. |
|
|
| Ongoing | 3 | 174 | Europe | zemplar, Hidroferol, 68022, Zemplar, Hidroferol, Zemplar, Hidroferol | Lorenzo Victor, PhD, Ministerio de Sanidad y Política Social (national health system) | Enfermedad renal crónica estadio II a IV más proteinuria residual >0,5 gr/día (en dos o más ocasiones consecutivas) más tratamiento con bloqueantes del SRAA durante al menos 3 meses. Niveles séricos de calcifediol en rango de insuficiencia (15-30 ng/ml). | | | | |
2009-016159-23: Vitamin D in addition to RAAS blockade and dietary sodium for the Treatment of Urinary Excretion of albumin: the ViRTUE-study |
|
|
| Ongoing | 3 | 30 | Europe | paricalcitol, ramipril, RVG 100436, RVG28004, paricalcitol, ramipril, paricalcitol, ramipril | University Medical Center Groningen (UMCG) | chronic kidney disease | | | | |
NCT04994080: A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism |
|
|
| Not yet recruiting | 3 | 84 | NA | Paricalcitol, Placebo | Chengdu Suncadia Medicine Co., Ltd. | Secondary Hyperparathyroidism | 03/23 | 03/23 | | |
NCT04064827: A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) |
|
|
| Recruiting | 3 | 16 | US | Paricalcitol | AbbVie | Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT) | 06/26 | 10/26 | | |
